1418 DACLATASVIR COMBINED WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN FOR 12 OR 16 WEEKS IN PATIENTS WITH HCV GENOTYPE 2 OR 3 INFECTION: COMMAND GT2/3 STUDY

Autor:	G.J. Dore, Stephen D. Shafran, Nina Weis, Maurizia Rossana Brunetto, Simone I. Strasser, Scott Fung, Daniel Cohen, P. Hagens, Alnoor Ramji, Serena Zaltron, Wayne Ghesquiere, Stanislas Pol, Eric Hughes, E. Lawitz, Harvey A Tatum, E. Cooney, Dominique Larrey, Hugh Harley, Stephanie Noviello, Albert Tran, Christophe Hézode, Gloria Taliani, Jacob George, V. de Ledinghen, Samuel S. Lee
Rok vydání:	2013
Předmět:	medicine.medical_specialty Daclatasvir Hepatology business.industry Ribavirin Rash Gastroenterology chemistry.chemical_compound chemistry Internal medicine Genotype medicine In patient medicine.symptom Adverse effect business Peginterferon alfa-2a medicine.drug
Zdroj:	Journal of Hepatology. 58:S570-S571
ISSN:	0168-8278
DOI:	10.1016/s0168-8278(13)61417-8
Popis:	All study medications were discontinued due to adverse events (AEs) in 4%, 4% and 5% of patients, and FDV only was discontinued in 0%, 1% and 3% of patients, respectively. Serious AEs occurred in 6%, 7% and 7% of patients. Grade 3 rash occurred in
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::e88720d846859b1c648736ae43df314a https://doi.org/10.1016/s0168-8278(13)61417-8 Zobrazit plný text záznamu Full Text from ScienceDirect